查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1413062

多重癌症筛检市场：按样本、测试类型、技术、癌症类型、最终用户 - 2024-2030 年全球预测

Multicancer Screening Market by Sample (Blood, Saliva & Buccal Swab, Tissue), Test Type (In-vitro diagnostics (IVDs), Laboratory Developed Tests (LDTs)), Technology, Cancer Type, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年多筛检市场规模为11.3亿美元，预计2024年将达12.4亿美元，2030年将达到21.1亿美元，复合年增长率为9.30%。

全球多种癌症筛检市场

主要市场统计
基准年[2023] 11.3亿美元
预测年份 [2024] 12.4亿美元
预测年份 [2030] 21.1亿美元
复合年增长率（%） 9.3%
多重癌症筛检市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估多癌症筛检市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对多种癌症筛检市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-多癌筛检市场的市场规模和预测是多少？

2-在多癌症筛检市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-多癌症筛检市场的技术趋势和法律规范是什么？

4-多种癌症筛检市场主要供应商的市场占有率为何？

5-进入多癌筛检市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率增加和人口老化
      • 对加强癌症早期检测程序的需求激增
      • 多项政府措施促进医疗机构中的多种癌症筛检
    • 抑制因素
      • 与多种癌症筛检相关的昂贵且耗时的步骤
    • 机会
      • 液体活体组织切片的潜在用途和多个癌症检测 (MCD) 研究中心的数量不断增加
      • 活性化研发活动以开发癌症诊断和治疗方法
    • 任务
      • 足够的安全性和有效性资料以及对试验表现变异性的担忧
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章多种筛检市场样本

  • 血
  • 唾液和口腔拭子
  • 组织

第七章按测试类型分類的多种筛检市场

  • 体外诊断（IVD）
  • 实验室开发测试 (LDT)

第八章多种筛检市场：依技术分类

  • 萤光原位杂合反应(FISH)
  • 免疫组织化学 (IHC)
  • 下一代定序（NGS）
  • 聚合酶炼式反应 (PCR)

第九章按癌症类型分類的多种癌症筛检市场

  • 大脑/神经系统
  • 乳房和妇科
  • 内分泌
  • 胃
  • 泌尿器官系统
  • 骨髓恶性肿瘤
  • 肺
  • 肉瘤
  • 皮肤

第 10 章 多种筛检市场：依最终用户分类

  • 学术/研究机构
  • 诊断和临床实验室
  • 医院

第十一章美洲多种癌症筛检市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区多种筛检市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲多癌症筛检市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第15章竞争组合

  • 主要公司简介
    • AnchorDx Medical Co., Ltd.
    • Anpac Bio-Medical Science Co., Ltd.
    • Burning Rock Biotech Limited
    • Caris Life Sciences
    • Delfi Diagnostics, Inc.
    • Elypta AB
    • EpiCypher, Inc.
    • Epigenomics AG
    • Exact Sciences Corporation
    • Foundation Medicine, Inc.
    • Freenome Holdings, Inc.
    • Grail, LLC by Illumina, Inc.
    • Guardant Health, Inc.
    • HLTH, INC.
    • Lucence Health Inc.
    • Micronoma, INC.
    • MiRXES Pte Ltd.
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • Naveris
    • StageZero Life Sciences. Ltd.
  • 主要产品系列

第十六章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-5C6F41F5AFFC

[191 Pages Report] The Multicancer Screening Market size was estimated at USD 1.13 billion in 2023 and expected to reach USD 1.24 billion in 2024, at a CAGR 9.30% to reach USD 2.11 billion by 2030.

Global Multicancer Screening Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.13 billion
Estimated Year [2024] USD 1.24 billion
Forecast Year [2030] USD 2.11 billion
CAGR (%) 9.3%
Multicancer Screening Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multicancer Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multicancer Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include AnchorDx Medical Co., Ltd., Anpac Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Grail, LLC by Illumina, Inc., Guardant Health, Inc., HLTH, INC., Lucence Health Inc., Micronoma, INC., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, and StageZero Life Sciences. Ltd..

Market Segmentation & Coverage

This research report categorizes the Multicancer Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Sample
    • Blood
    • Saliva & Buccal Swab
    • Tissue
  • Test Type
    • In-vitro diagnostics (IVDs)
    • Laboratory Developed Tests (LDTs)
  • Technology
    • Fluorescence In-Situ Hybridization (FISH)
    • Immunohistochemistry (IHC)
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
  • Cancer Type
    • Brain/Nervous System
    • Breast & Gynecologic
    • Endocrine
    • Gastrointestinal
    • Genitourinary
    • Hematological Malignancies
    • Lung
    • Sarcoma
    • Skin
  • End User
    • Academic & Research Institutions
    • Diagnostic & Clinical Laboratories
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multicancer Screening Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multicancer Screening Market?

3. What are the technology trends and regulatory frameworks in the Multicancer Screening Market?

4. What is the market share of the leading vendors in the Multicancer Screening Market?

5. Which modes and strategic moves are suitable for entering the Multicancer Screening Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Multicancer Screening Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disease and rising aging population
      • 5.1.1.2. Surge in demand for enhanced early detection procedures of cancers
      • 5.1.1.3. Several government initiatives promoting multicancer screening in healthcare facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Time-consuming procedures coupled with high cost associated with multicancer screening
    • 5.1.3. Opportunities
      • 5.1.3.1. Potential utilization of liquid biopsy and rising multi-cancer detection (MCD) research centers
      • 5.1.3.2. Rising R&D activities for the development of cancer diagnostics treatment procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Concern associated with adequate safety and efficacy data and variability in test performance
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Multicancer Screening Market, by Sample

  • 6.1. Introduction
  • 6.2. Blood
  • 6.3. Saliva & Buccal Swab
  • 6.4. Tissue

7. Multicancer Screening Market, by Test Type

  • 7.1. Introduction
  • 7.2. In-vitro diagnostics (IVDs)
  • 7.3. Laboratory Developed Tests (LDTs)

8. Multicancer Screening Market, by Technology

  • 8.1. Introduction
  • 8.2. Fluorescence In-Situ Hybridization (FISH)
  • 8.3. Immunohistochemistry (IHC)
  • 8.4. Next-Generation Sequencing (NGS)
  • 8.5. Polymerase Chain Reaction (PCR)

9. Multicancer Screening Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Brain/Nervous System
  • 9.3. Breast & Gynecologic
  • 9.4. Endocrine
  • 9.5. Gastrointestinal
  • 9.6. Genitourinary
  • 9.7. Hematological Malignancies
  • 9.8. Lung
  • 9.9. Sarcoma
  • 9.10. Skin

10. Multicancer Screening Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Diagnostic & Clinical Laboratories
  • 10.4. Hospitals

11. Americas Multicancer Screening Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Multicancer Screening Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Multicancer Screening Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. AnchorDx Medical Co., Ltd.
    • 15.1.2. Anpac Bio-Medical Science Co., Ltd.
    • 15.1.3. Burning Rock Biotech Limited
    • 15.1.4. Caris Life Sciences
    • 15.1.5. Delfi Diagnostics, Inc.
    • 15.1.6. Elypta AB
    • 15.1.7. EpiCypher, Inc.
    • 15.1.8. Epigenomics AG
    • 15.1.9. Exact Sciences Corporation
    • 15.1.10. Foundation Medicine, Inc.
    • 15.1.11. Freenome Holdings, Inc.
    • 15.1.12. Grail, LLC by Illumina, Inc.
    • 15.1.13. Guardant Health, Inc.
    • 15.1.14. HLTH, INC.
    • 15.1.15. Lucence Health Inc.
    • 15.1.16. Micronoma, INC.
    • 15.1.17. MiRXES Pte Ltd.
    • 15.1.18. Myriad Genetics, Inc.
    • 15.1.19. Natera, Inc.
    • 15.1.20. Naveris
    • 15.1.21. StageZero Life Sciences. Ltd.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. MULTICANCER SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. MULTICANCER SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MULTICANCER SCREENING MARKET DYNAMICS
  • FIGURE 7. MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
  • FIGURE 8. MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 10. MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 12. MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 14. MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 26. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 6. MULTICANCER SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MULTICANCER SCREENING MARKET SIZE, BY SALIVA & BUCCAL SWAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MULTICANCER SCREENING MARKET SIZE, BY TISSUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. MULTICANCER SCREENING MARKET SIZE, BY IN-VITRO DIAGNOSTICS (IVDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TESTS (LDTS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 13. MULTICANCER SCREENING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION (FISH), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. MULTICANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. MULTICANCER SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. MULTICANCER SCREENING MARKET SIZE, BY BRAIN/NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. MULTICANCER SCREENING MARKET SIZE, BY BREAST & GYNECOLOGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. MULTICANCER SCREENING MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. MULTICANCER SCREENING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. MULTICANCER SCREENING MARKET SIZE, BY GENITOURINARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. MULTICANCER SCREENING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. MULTICANCER SCREENING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. MULTICANCER SCREENING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. MULTICANCER SCREENING MARKET SIZE, BY SKIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. MULTICANCER SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC & CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 241. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. MULTICANCER SCREENING MARKET LICENSE & PRICING